A phase 4 clinical trial completed in 2020 examined the relationship between insulin resistance and statin-induced T2DM using high-dose atorvastatin and was able to show increased insulin resistance and insulin secretion in the high-dose atorvastatin group [24]. This evidence concerns the gene INS and Insulin resistance.